Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET

Company Participants

Clayton Robertson - Head, IR

Bahija Jallal - CEO

Ralph Torbay - Head, Commercial

David Berman - Head, R&D

Brian Di Donato - CFO

Mohammed Dar - CMO

Conference Call Participants

Michael Yee - Jefferies

Jessica Fye - JP Morgan

Tyler Van Buren - TD Cowen

Eric Schmidt - Cantor Fitzgerald

Paul Jeng - Guggenheim

Avantika Joshi - Mizuho

Peter Lawson - Barclays

Charlie Moore - Baird

Jeet Mukherjee - BTIG

Patrick Trucchio - H.C. Wainwright

Gil Blum - Needham

Naureen Quibria - Capital One Securities

Michael Riad - Morgan Stanley

Ahu Demir - Ladenburg

Rajan Sharma - Goldman Sachs

Operator

Greetings. Welcome to the Immunocore Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note this conference is being recorded.

I'll now turn the conference over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.

Clayton Robertson

Thank you, Darryl. Welcome everyone to our Q4 and full year 2023 financial results call.

Before we begin, I would like to remind you that this call will contain forward-looking statements within the meaning of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. These include expectation, plans, concerning future events, prospects and performance, including with respect to commercialization, clinical development and trials, regulatory approvals and financial results. Actual events may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those disclosed in our filings with the SEC. And such statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.

With that, I'm now pleased to introduce Immunocore CEO, Dr. Bahija Jallal.

Bahija Jallal

Thank you, Clay. Hello, everyone.

With me today are Ralph Torbay, our Head of Commercial; David Berman, our Head of R&D; and Brian Di Donato, our Chief Financial Officer. We will be happy to take your questions at the end.

At Immunocore, we are driven by a clear mission to bring transformative immunomodulating medicines to patients. In 2023, we continue to advance our three strategic pillars of maximizing the potential of KIMMTRAK, advancing our clinical portfolio, and continuing to innovate for sustainable growth.